RxDoctor Payments Data

Latonia Ward, MD

Nephrology · Springfield Gardens, NYNPI 1821028424

Payments from drug & device makers

$5,956in general payments, 2019–2025

Across 270 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • OPKO Pharmaceuticals, LLC$859
  • AstraZeneca$644
  • Bayer$625
  • Vanda Pharmaceuticals Inc.$526
  • Lilly USA, LLC$499
  • Dexcom, Inc.$432
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,46392%
  • Education$4938%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,956 in reported general payments places this provider in the 75th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$66,180
Medicare patients
80
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayaldeeCalcifediol17$58,308
EliquisApixaban15$13,099
Sevelamer Carbonate38$11,823
Potassium Chloride30$2,866
Allopurinol214$2,670
Nifedipine ErNifedipine51$1,496
Metoprolol Succinate44$1,484
Atorvastatin Calcium87$1,369
Amlodipine Besylate133$822
Calcitriol30$721
Albuterol Sulfate HfaAlbuterol Sulfate17$638
Hydralazine Hcl26$465
Ezetimibe12$417
Olmesartan Medoxomil11$312
Losartan Potassium50$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
OPKO Pharmaceuticals, LLCRayaldee$859$58,30817 claims
PfizerEliquis$16$13,09915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 nephrology providers in New York.

Other nephrology in Springfield Gardens

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →